JNK2 and p38 MAPK over-expressions do not represent key events in chronic myeloid leukemia transformation

Neoplasma

Volumn 54, Issue 6, 2007, Pages 503-510

  Merkerova, M ^a   Bruchova, H ^a   Brdicka, R ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

CML; Expression arrays; JNK2; MAPK; p38; siRNA

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; SMALL INTERFERING RNA; MITOGEN ACTIVATED PROTEIN KINASE 9;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BIOSYNTHESIS; CELL TRANSFORMATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GENETICS; METABOLISM; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MITOGEN-ACTIVATED PROTEIN KINASE 9; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION;

EID: 38949098302     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. COBB MH. MAP kinase pathways. Prog Biophys Mol Biol 1999; 71: 479-500.
2. DAVIS RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-252.
3. ONO K, HAN J. The p38 signal transduction pathway: activation and function. Cell Signal 2000; 12: 1-13. (Pubitemid 30017963)
4. LIN A. Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays 2003; 25: 17-24.
5. DU L, LYLE CS, OBEY TB, et al. Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic Bcl-2 phosphorylation is JNK-independent. J Biol Chem 2004; 279: 11957-11966.
6. POTAPOVA O, GOROSPE M, BOST F, et al. c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J Biol Chem 2000; 275: 24767-24775. (Pubitemid 30626580)
7. HRENIUK D, GARAY M, GAARDE W, et al. Inhibition of c-Jun N-terminal kinase 1, but not c-Jun N-terminal kinase 2, suppresses apoptosis induced by ischemia/reoxygenation in rat cardiac myocytes. Mol Pharmacol 2001; 59: 867-874.
8. HOCHEDLINGER K, WAGNER EF, SABAPATHY K. Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis. Oncogene 2002; 21: 2441-2445.
9. SABAPATHY K, HOCHEDLINGER K, NAM SY, et al. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell 2004; 15: 843-844.
10. MACCORKLE RA, TAN TH. Inhibition of JNK2 disrupts anaphase and produces aneuploidy in mammalian cells. J Biol Chem 2004; 279: 40112-40121.
11. CHEN N, NOMURA M, She QB, et al. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res 2001; 61: 3908-3912.
12. TSUIKI H, TNANI M, OKAMOTO I, et al. Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer Res 2003; 63: 250-255.
13. ZARUBIN T, HAN J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005; 15: 11-18. (Pubitemid 41653958)
14. DEININGER MW, GOLDMAN JM, MELO JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356. (Pubitemid 30836310)
15. RAITANO AB, HALPERN JR, HAMBUCH TM, et al. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A 1995; 92: 11746-11750.
16. WEISBERG E, MANLEY PW, BREITENSTEIN W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7:129-141.
17. GUMIREDDY K, BAKER SJ, COSENZA SC, et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A 2005; 102:1992-1997.
18. WOLFF NC, VEACH DR, TONG WP, et al. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 2005; 105: 3995-4003.
19. PTASZNIK A, NAKATA Y, KALOTA A, et al. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 2004; 10: 1187-1189.
20. SCHERR M, CHATURVEDI A, BATTMER K, et al. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 2006; 107: 3279-3287.
21. BRUCHOVA H, KLAMOVA H, BRDICKA R. Gene expression in chronic myeloid leukemia patients at time of diagnosis. Cas Lek Ces 2000; 139: 655-659.
22. BRUCHOVA H, BOROVANOVA T, BRDICKA R. Gene expression in patients with chronic myeloid leukemia. BIO-forum International 2001; 5: 259-261.
23. BRUCHOVA H, BOROVANOVA T, KLAMOVA H, BRDICKA R. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea. Leukemia and Lymphoma 2002; 43: 1289-1295. (Pubitemid 34537975)
24. PARMAR S, KATSOULIDIS E, VERMA A, et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 2004; 279: 25345-25352.
25. MAYER IA, VERMA A, GRUMBACH IM, et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem 2001; 276: 28570-28577. (Pubitemid 37391572)
26. KOHMURA K, MIYAKAWA Y, KAWAI Y, et al. Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells. J Cell Physiol 2004; 198: 370-376.
27. CHOMCZYNSKY P, SACCHI N. Single step method of RNA isolation by acid guanidin-isothiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159.
28. MERKEROVA M, BRUCHOVA H, BRDICKA R. Expression analysis of PCNA gene in chronic myelogenous leukemia-Combined application of siRNA silencing and expression arrays. Leuk Res 2006; in press.
29. GALAKTIONOV K, LEE AK, ECKSTEIN J, et al. CDC25 phosphatases as potential human oncogenes. Science 1995; 269: 1575-1577.
30. TAKEMASA I, YAMAMOTO H, SEKIMOTO M, et al. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res 2000; 60: 3043-3050.
31. BULAVIN DV, FORNACE AJ Jr. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 2004; 92: 95-118.
32. YASMEEN A, BERDEL WE, SERVE H, et al. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn 2003; 3: 617-633. (Pubitemid 37101877)
33. SMITH MR, WILSON ML, HAMANAKA R, et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997; 234: 397-405.
34. JIANG ZH, ZHANG WJ, RAO Y, et al. Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. Proc Natl Acad Sci U S A 1998; 95: 9155-9160. (Pubitemid 28506201)
35. SULCINER DJ, IRANI K, YU ZX, et al. Rac1 regulates a cytokine-stimulated, redox-dependent pathway necessary for NF-kappaB activation. Mol Cell Biol 1996; 16: 7115-7121.
36. LEE NK, LEE SY. Modulation of life and death by the tumor necrosis factor receptor-associated factors (TRAFs). J Biochem Mol Biol 2002; 35: 61-66.
37. COSO OA, CHIARIELLO M, YU JC, et al. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995; 81: 1137-1146.
38. BRADLEY JR, POBER JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001; 20: 6482-6491. (Pubitemid 32977853)
39. LANGLAIS P, DONG LQ, RAMOS FJ, et al. Negative regulation of insulin-stimulated mitogen-activated protein kinase signaling by Grb10. Mol Endocrinol 2004; 18: 350-358. (Pubitemid 38183934)
40. WESTON CR, WONG A, HALL JP, et al. The c-Jun NH2-terminal kinase is essential for epidermal growth factor expression during epidermal morphogenesis. Proc Natl Acad Sci U S A 2004; 101: 14114-14119. (Pubitemid 39305039)
41. VERGARAJAUREGUI S, SAN MIGUEL A, PUERTOLLANO R. Activation of p38 mitogen-activated protein kinase promotes epidermal growth factor receptor internalization. Traffic 2006; 7: 686-698. (Pubitemid 43676977)